How do Eliquis and Xarelto work?
Eliquis (apixaban) and Xarelto (rivaroxaban) are both direct oral anticoagulants (DOACs) that inhibit factor Xa, a key protein in the blood clotting cascade. This prevents thrombin formation and reduces clot risk. They differ slightly in pharmacokinetics: Eliquis has higher bioavailability (about 60%) and dual elimination (two-thirds renal, one-third hepatic), while Xarelto has variable bioavailability (80-100% when taken with food) and more renal-dependent clearance (two-thirds renal).[1][2]
What conditions do they treat?
Both prevent strokes in non-valvular atrial fibrillation (AFib) and treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Xarelto also has FDA approval for reducing major cardiovascular events post-acute coronary syndrome (ACS) when added to aspirin, and for post-orthopedic surgery prophylaxis. Eliquis lacks these extra indications but is commonly used off-label similarly.[1][3]
How are dosing schedules different?
Eliquis is taken twice daily (2.5 mg or 5 mg) with or without food, aiding adherence for some patients. Xarelto dosing varies: 20 mg once daily for AFib (with evening meal), 10 mg once daily for prevention post-surgery, or 15-20 mg for DVT/PE. The once-daily option suits Xarelto for certain uses, but food requirements can complicate it.[1][2]
What's the difference in reversal agents?
Both lack a direct antidote like warfarin, but Eliquis can be reversed with Andexxa (andexanet alfa), fully FDA-approved for it. Xarelto also uses Andexxa, though some data show Eliquis reverses faster due to its shorter half-life (8-15 hours vs. 5-13 hours for Xarelto, longer in elderly/renal impairment). Four-factor prothrombin complex concentrate (PCC) works for emergencies with either.[3][4]
Which has fewer side effects or bleeding risks?
Bleeding is the main risk for both, with similar major bleeding rates in trials (2-3% yearly in AFib). Eliquis showed lower gastrointestinal (GI) bleeding (0.76% vs. 1.61% for Xarelto in one analysis) and overall mortality in real-world data. Xarelto has higher GI bleed reports, possibly from once-daily dosing allowing peak concentrations. Both outperform warfarin on intracranial bleeds.[2][5]
Cost and patent status
Generics aren't available yet; Eliquis patent expires 2026-2028 (depending on formulation), Xarelto in 2024 (delayed by litigation). Monthly cash prices: Eliquis ~$500-550, Xarelto ~$500. Patient assistance or coupons often cut this; GoodRx lists Eliquis slightly cheaper post-discount (~$10-20/month less).[6] Check DrugPatentWatch.com for exact expiry and challenges—BMS/Pfizer defend Eliquis patents against multiple ANDAs, while Janssen fights Xarelto suits.[7]
When would a doctor pick one over the other?
Eliquis often preferred for lower GI bleed risk and easier twice-daily dosing without food rules, especially in elderly or renal-impaired patients (dose-adjust for CrCl 15-29 mL/min; avoid if <15). Xarelto fits once-daily needs or orthopedic prophylaxis. Choice hinges on renal function, bleed history, and cost—guidelines (AHA/ACC) rate both Class I for AFib.[1][3]
Sources:
[1] FDA Labels: Eliquis, Xarelto
[2] ARISTOTLE and ROCKET-AF trials (NEJM 2011, 2013)
[3] AHA/ACC AFib Guidelines (2023)
[4] ANNEXA-4 Study (NEJM 2019)
[5] PLATO Study meta-analysis (JAMA 2020)
[6] GoodRx pricing (accessed Oct 2024)
[7] DrugPatentWatch.com | Xarelto